Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Is TEVA a good investment?
Teva Pharmaceutical Industries Limited (TEVA) has a Plutrex AI rating of 62.5/100 as of May 26, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability with ROE of 21.4% and operating margin of 27.3%, both significantly above industry averages. Main concern: High debt-to-equity ratio of 1.93 (151% above industry) creating significant financial leverage risk.
Investment Summary
TEVA presents a complex investment case with exceptional profitability metrics (ROE 21.4% vs industry 9.9%, operating margin 27.3% vs 15.8%) but significant structural challenges. The company trades at a massive 82.7% discount to industry PE (28.06 vs 161.94) despite superior operational efficiency. However, the debt-to-equity ratio of 1.93 (151% above industry average) and modest 5.5% five-year growth projection create substantial headwinds. Recent positive news on duvakitug IBD treatment and strong Q4 earnings provide near-term catalysts, but the PEG ratio of 2.01 suggests overvaluation relative to growth prospects.
Key Strengths
- Exceptional profitability with ROE of 21.4% and operating margin of 27.3%, both significantly above industry averages
- Strong cash generation with $2.03 billion free cash flow and $3.56 billion cash reserves providing financial flexibility
- Positive clinical trial results for duvakitug IBD treatment opening new revenue opportunities
Key Concerns
- High debt-to-equity ratio of 1.93 (151% above industry) creating significant financial leverage risk
- Modest 5.5% five-year growth projection significantly below industry average of 12.4%
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
TEVA demonstrates exceptional operational performance with ROE of 21.4% (116% above industry 9.9%) and operating margin of 27.3% (72% above industry 15.8%), indicating superior management efficiency. Free cash flow of $2.03 billion provides strong cash generation capability. However, the debt-to-equity ratio of 1.93 vs industry 0.77 creates significant financial risk. Growth metrics are concerning with forward 5-year EPS growth of only 5.5% vs industry 12.4% (-55% discount). The PEG ratio of 2.01 indicates investors are paying a premium for modest growth, while the massive PE discount (28.06 vs 161.94) suggests market skepticism about the business model sustainability. Additional metrics: PE Ratio: 28.06
News Sentiment
Teva Pharmaceutical is experiencing a renaissance moment as the Israeli drugmaker delivers encouraging updates across multiple fronts. The company recently announced positive results from its duvakitug phase 2b maintenance study for inflammatory bowel disease, showing 'clinically meaningful durable efficacy' that could open doors to a lucrative specialized treatment market. This breakthrough comes alongside strong fourth-quarter earnings that beat expectations, with both profit and revenue rising significantly. However, investors showed mixed reactions to the company's 2026 financial outlook, which some viewed as conservative despite the recent operational improvements. Adding to the positive momentum, Teva received favorable assessment through Zacks Style Scores methodology, providing third-party validation that may boost investor confidence. The combination of promising drug pipeline developments and solid financial performance suggests Teva is successfully navigating its transformation from a generic drug giant to a more diversified pharmaceutical company. While the market initially showed some hesitation about the long-term guidance, the underlying business fundamentals and pipeline progress indicate the company is building sustainable competitive advantages in specialized therapeutic areas.
Risk Assessment
Primary risks include high debt burden limiting financial flexibility, modest growth prospects in competitive pharmaceutical market, and potential interest rate sensitivity due to leverage. Regulatory risks for drug approvals and generic competition pose ongoing threats. Mitigation strategies include monitoring debt reduction progress, diversification across pharmaceutical holdings, and position sizing appropriate for risk level.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is TEVA a halal stock?
No, Teva Pharmaceutical Industries Limited (TEVA) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for TEVA?
Teva Pharmaceutical Industries Limited (TEVA) has a Plutrex AI rating of 62.5/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is TEVA a good investment?
According to Plutrex AI, TEVA has a Hold rating (62.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in TEVA?
US stocks like TEVA can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in TEVA?
Plutrex AI identifies the main risks for TEVA by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.